1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
654488E61C2D5B39B85257E530072F7F1
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-tecfidera-case-study-using-safety-as-a-springboard-for-blockbuster-status?OpenDocument
18
19OpenDocument
2034.229.126.29
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Sales and Marketing New Product Development and Launch Planning and Coordinating Launch Communication Activities

Tecfidera Case Study: Using Safety as a Springboard for Blockbuster Status

ID: 5360


Features:

16 Info Graphics

3 Data Graphics

36 Metrics

5 Narratives


Pages/Slides: 27


Published: 2015


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Tecfidera Case Study: Using Safety as a Springboard for Blockbuster Status"

STUDY OVERVIEW

When it was approved in March 2013, Tecfidera was the third oral drug for relapse remitting multiple sclerosis (MS). Yet Biogen's Tecfidera outperformed all other MS drugs in its first three months on the market. In its first four quarters on the market, Tecfidera generated $1.4 billion in sales.

How?

While Tecfidera's efficacy was comparable to its competitors, the new drug's safety profile was considered superior. Biogen used that advantage and also strategically priced Tecfidera so it was less than its main competitor Gilenya but more than the less popular Anbagio. This case study examines how Biogen used safety and pricing to differentiate Tecfidera from competitors and catapult the MS drug to blockbuster status.

KEY TOPICS

  • Product Overview
  • Safety Profile
  • Launch Success
  • Commercialization
  • Global Market
  • Next Challenge

SAMPLE KEY METRICS
  • Tecfidera Physician Trial Rate 2013
  • Tecfidera Quarterly Sales 2013
  • Biogen MS Product Revenues 2013
  • Tecfidera, Gilenya and Aubagio Pricing

METHODOLOGY

This study was produced using secondary research.

Industries Profiled:
Biotech; Manufacturing; Health Care; Pharmaceutical; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Biogen; Sanofi; Novartis


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.